Britain's FTSE nears record high as Shire shines

* FTSE 100 up 0.5 pct, near record highs

* Property stocks on the rise

* Shire (Xetra: S7E.DE - news) rises but AstraZeneca (NYSE: AZN - news) falls

* Election uncertainty fails to spread to stocks

By Sudip Kar-Gupta

LONDON, April 10 (Reuters) - Britain's top equity index advanced on Friday, nearing record highs, as real-estate stocks extended gains from a rebound in property prices and drugmaker Shire got a lift from a positive product review.

The FTSE 100 rose 0.5 percent to 7,051.07 points, close to a record 7,065.08 points reached in March.

Even (Taiwan OTC: 6436.TWO - news) though uncertainty before next month's British election has weakened sterling, the benchmark UK stock market has continued to push higher.

Sterling got another knock after the UK reported industrial output barely grew in February, but equity traders said a weak pound could help British exporters and that individual companies were still seeing a lot of positive developments.

Shire shares rose 5.2 percent, the biggest gain on the FTSE 100, from a U.S. Food and Drug Administration decision to grant a priority review to its application for lifitegrast, a dry-eye disease treatment.

Homebuilders Barratt Developments and Taylor Wimpey (LSE: TW.L - news) rose as did property-listing company Zoopla, a day after data pointed to a rebound in British house-price growth in March.

"Whatever form a new British coalition government takes, the UK still has a massive need to build more homes," said Charles Hanover Investments' partner Dafydd Davies.

ITV AT 15-YEAR HIGH

TV and media company ITV (LSE: ITV.L - news) rose to a 15-year high after investment bank Morgan Stanley (Xetra: 885836 - news) raised its price target on the stock.

However, mining stocks including Anglo American (LSE: AAL.L - news) , Glencore (Xetra: A1JAGV - news) and Rio Tinto (Xetra: 855018 - news) fell, hit by a renewed slide in prices for iron ore.

Drugmaker AstraZeneca also fell after a negative review for Astra's diabetes drug Onglyza.

While neither the Conservatives nor the Labour Party is forecast to win an overall majority in Britain's 650-seat parliament, Richard Buxton, head of UK equities at Old Mutual (Other OTC: ODMTY - news) Global Investors, said he was making no short-term portfolio changes and sticking to financial and cyclical stocks.

Beaufort Securities sales trader Basil Petrides, however, was adopting a more cautious attitude.

"I can't buy into the market here. I would rather be taking some money off the table." (Additional reporting by Lionel Laurent; Editing by Tom Heneghan)